S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$14.74
$14.75
50-Day Range
$14.42
$14.75
52-Week Range
$6.38
$14.76
Volume
3.45 million shs
Average Volume
3.08 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75

BELLUS Health MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
0.1% Upside
$14.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.97) to ($1.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.10 out of 5 stars

Medical Sector

931st out of 938 stocks

Biotechnology Industry

46th out of 47 stocks

BLU stock logo

About BELLUS Health Stock (NASDAQ:BLU)

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

BLU Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
CBD Dosage: How Much Should You Take?
Bellus Health (NASDAQ: BLU)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
BLU.TO - BELLUS Health Inc.
BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)
Closing Bell: Bellus Health Inc up on Tuesday (BLU)
BELLUS Health Announces Meeting Updates
LifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)
Why BELLUS Health Stock Is Rocketing Higher Today
See More Headlines
Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLU
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.75
High Stock Price Target
$14.75
Low Stock Price Target
$14.75
Potential Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-76,080,000.00
Net Margins
-578,586.63%
Pretax Margin
-578,226.56%

Debt

Sales & Book Value

Annual Sales
$15,000.00
Price / Sales
124,613.93
Book Value
$3.09 per share

Miscellaneous

Free Float
96,162,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
0.19
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Roberto Francesco BelliniMr. Roberto Francesco Bellini (Age 43)
    Pres, CEO & Director
    Comp: $790.35k
  • Mr. Ramzi Benamar (Age 50)
    Chief Financial Officer
    Comp: $650.48k
  • Dr. Andreas Orfanos FFPM (Age 64)
    M.B.B.Ch, MBA, Chief Operating Officer
    Comp: $417.58k
  • Dr. Denis Garceau Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $496.56k
  • Dr. Catherine M. Bonuccelli M.D. (Age 65)
    Chief Medical Officer
    Comp: $741.66k
  • Mr. Daniel Matthews
    Director of Investor Relations & Communications
  • Mr. Tony Matzouranis (Age 50)
    Chief Bus. Officer
  • Mr. Sebastien Roy (Age 47)
    Corp. Sec.

BLU Stock Analysis - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLU shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLU, but not buy additional shares or sell existing shares.
View BLU analyst ratings
or view top-rated stocks.

What is BELLUS Health's stock price target for 2024?

4 brokerages have issued 1 year price objectives for BELLUS Health's shares. Their BLU share price targets range from $14.75 to $14.75. On average, they predict the company's share price to reach $14.75 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for BLU
or view top-rated stocks among Wall Street analysts.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) announced its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.07. BELLUS Health had a negative net margin of 578,586.63% and a negative trailing twelve-month return on equity of 24.27%.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

This page (NASDAQ:BLU) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners